InsiderTrades.com logo
Adrian Rawcliffe net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Adrian Rawcliffe Biography and Net Worth

Director of WAVE Life Sciences

Adrian Rawcliffe serves as the Chief Executive Officer and on the board of directors at Adaptimmune Therapeutics plc, where he also previously served as their Chief Financial Officer. He has more than 20 years of experience within the pharmaceutical and biotechnology industries and previously served as Senior Vice President, Finance of GlaxoSmithKline’s (GSK) North American Pharmaceuticals business. Mr. Rawcliffe joined GSK in 1998 and his other senior roles at the company included Senior Vice President Worldwide Business Development and R&D Finance, where he was responsible for all business development and finance activities for GSK’s Pharmaceuticals R&D business and Managing Partner and President of SR One Ltd, GSK’s venture capital business. Mr. Rawcliffe qualified as a chartered accountant with PricewaterhouseCoopers and holds a B.Sc. degree in Natural Sciences from the University of Durham, U.K.

What is Adrian Rawcliffe's net worth?

The estimated net worth of Adrian Rawcliffe is at least $164.34 thousand as of December 8th, 2025. Rawcliffe owns 12,700 shares of WAVE Life Sciences stock worth more than $164,338 as of January 31st. This net worth approximation does not reflect any other assets that Rawcliffe may own. Learn More about Adrian Rawcliffe's net worth.

How do I contact Adrian Rawcliffe?

The corporate mailing address for Rawcliffe and other WAVE Life Sciences executives is 7 STRAITS VIEW #12-00 MARINA ONE EAST TOWER, SINGAPORE U0, 018936. WAVE Life Sciences can also be reached via phone at (656) 236-3388 and via email at [email protected]. Learn More on Adrian Rawcliffe's contact information.

Has Adrian Rawcliffe been buying or selling shares of WAVE Life Sciences?

Adrian Rawcliffe has not been actively trading shares of WAVE Life Sciences during the last quarter. Most recently, Adrian Rawcliffe sold 42,000 shares of the business's stock in a transaction on Monday, December 8th. The shares were sold at an average price of $15.00, for a transaction totalling $630,000.00. Following the completion of the sale, the director now directly owns 12,700 shares of the company's stock, valued at $190,500. Learn More on Adrian Rawcliffe's trading history.

Who are WAVE Life Sciences' active insiders?

WAVE Life Sciences' insider roster includes Paul Bolno (CEO), Mark Corrigan (Director), Chris Francis (insider), Christian Henry (Director), Kyle Moran (CFO), Adrian Rawcliffe (Director), Ken Takanashi (Director), Gregory Verdine (Director), and Heidi Wagner (Director). Learn More on WAVE Life Sciences' active insiders.

Are insiders buying or selling shares of WAVE Life Sciences?

In the last twelve months, WAVE Life Sciences insiders bought shares 1 times. They purchased a total of 1,470,000 shares worth more than $27,930,000.00. In the last twelve months, insiders at the sold shares 17 times. They sold a total of 1,363,535 shares worth more than $17,815,766.35. The most recent insider tranaction occured on January, 2nd when insider Chris Francis sold 9,375 shares worth more than $150,281.25. Insiders at WAVE Life Sciences own 24.0% of the company. Learn More about insider trades at WAVE Life Sciences.

Information on this page was last updated on 1/2/2026.

Adrian Rawcliffe Insider Trading History at WAVE Life Sciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/8/2025Sell42,000$15.00$630,000.0012,700View SEC Filing Icon  
11/13/2025Sell16,115$6.79$109,420.8512,700View SEC Filing Icon  
See Full Table

Adrian Rawcliffe Buying and Selling Activity at WAVE Life Sciences

This chart shows Adrian Rawcliffe's buying and selling at WAVE Life Sciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

WAVE Life Sciences Company Overview

WAVE Life Sciences logo
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.
Read More

Today's Range

Now: $12.94
Low: $12.75
High: $13.21

50 Day Range

MA: $14.03
Low: $6.99
High: $21.31

2 Week Range

Now: $12.94
Low: $5.28
High: $21.73

Volume

2,326,426 shs

Average Volume

4,587,866 shs

Market Capitalization

$2.16 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A